CLINICAL TRIAL: PHOSPHODIESTE RASE-5 INHIBITION IN DIASTOLIC HEART FAILURE (RELA

临床试验：磷酸二酯酶 5 抑制舒张性心力衰竭 (RELA

• 批准号: 8166988
• 负责人: MARTIN M LEWINTER
• 金额: $ 2.82万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166988
• 关键词: Chronic; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Diastolic heart failure; Double-Blind Method; EFRAC; Exercise; Funding; Grant; Heart failure; Institution; Measures; Patients; Performance; Placebos; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; improved; inhibitor/antagonist; placebo controlled study; sildenafil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a double-blind, placebo controlled study testing the hypothesis that chronic PDE-5 inhibition (sildenafil 80 mg tid for 24 weeks) improves exercise capacity and clinical status in patients with heart failure and normal ejection fraction. This study also measures the effect of this therapy on key pathophysiological parameters which are postulated to impact clinical status and exercise performance in diastolic heart failure. 120 patients will be studied. Approximately 10 here at FAHC. The primary endpoint is change in exercise capacity as assessed by peak VO2 after 24 weeks of double-blinded treatment PDE-5 inhibitor or placebo.

这个子项目是众多研究子项目之一